Effects of losartan tablets in the treatment and modification of liver function in patients with non-alcoholic fatty liver

Effects of losartan drug on liver function tests in patients with non alcoholic steatohepatitis (NASH)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016060628305N1

Enrollment

100

Registered

2016-08-14

Start date

2016-07-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver function in non alcoholic steatohepatitis (NASH) patients. Abnormal results of liver function studies

Interventions

Intervention 1: In the intervention group, Losartan 50 mg tablet taken orally, once a day for six months. Intervention 2: In the control group, Amlodipine 5 mg tablets orally, once a day for six mont

Treatment - Drugs

In the intervention group, Losartan 50 mg tablet taken orally, once a day for six months

In the control group, Amlodipine 5 mg tablets orally, once a day for six months

Eligibility

Sex/Gender

All

Age

98 Years to 56 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age > 18 years old; Chronic hypertension. Exclusion criteria: Viral hepatitis; Human immunodeficiency virus positive; Pregnancy; Diabetes; Daily alcohol consumption; Use of drugs affecting liver enzymes in the last 6 months; A history of liver disease; Kidney disease; Chronic debilitating disease; Gastrointestinal bleeding active in the last 6 months ; Consumption previous and current weight loss or lipid drugs; Anti-TNFa; Stimulant drugs insulin; Metformin ; Vitamin E; Pentoxifylline

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Aspartate aminotransferase. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Alanine aminotransferase. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Alkaline phosphatase. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Triglyceride. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Cholesterol. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.	—

Measure

Time frame

Aspartate aminotransferase. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Alanine aminotransferase. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Alkaline phosphatase. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Triglyceride. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.;Cholesterol. Timepoint: Before starting treatment, every two months to six months after treatment. Method of measurement: Blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Sharifi MD.

Sina Hospital

sharifra@tums.ac.ir+98 21 6634 8500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026